Sonoma Pharmaceuticals (SNOA) 10-Q 14 Feb 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2022	Feb. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	001-33216
Entity Registrant Name	SONOMA PHARMACEUTICALS, INC.
Entity Central Index Key	0001367083
Entity Tax Identification Number	68-0423298
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	5445 Conestoga Court
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	(800)
Local Phone Number	759-9305
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	SNOA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,649,247

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,634	$ 7,396
Accounts receivable, net	2,297	2,407
Inventories, net	2,849	2,663
Prepaid expenses and other current assets	3,230	3,746
Current portion of deferred consideration, net of discount	222	218
Total current assets	11,232	16,430
Property and equipment, net	314	320
Operating lease, right of use assets	471	559
Deferred tax asset	1,089	829
Deferred consideration, net of discount, less current portion	514	630
Other assets	308	77
Total assets	13,928	18,845
Current liabilities:
Accounts payable	1,302	1,641
Accrued expenses and other current liabilities	2,201	1,843
Deferred revenue	100	1,223
Deferred revenue Invekra	55	54
Current portion of debt-PPP	0	120
Short-term debt	0	688
Operating lease liabilities	276	250
Total current liabilities	3,934	5,819
Long-term deferred revenue Invekra	128	182
Long-term debt	15	0
Withholding tax payable	4,097	3,838
Operating lease liabilities, less current portion	195	309
Total liabilities	8,369	10,148
Stockholders’ Equity:
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2022 and March 31, 2022, respectively, no shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively	0	0
Common stock, $0.0001 par value; 24,000,000 shares authorized at December 31, 2022 and March 31, 2022, respectively, 3,109,652 and 3,100,937 shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively (Note 7)	2	2
Additional paid-in capital	197,939	197,370
Accumulated deficit	(188,206)	(184,363)
Accumulated other comprehensive loss	(4,176)	(4,312)
Total stockholders’ equity	5,559	8,697
Total liabilities and stockholders’ equity	$ 13,928	$ 18,845

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	24,000,000	24,000,000
Common stock shares issued	3,109,652	3,100,937
Common stock shares outstanding	3,109,652	3,100,937
Convertible Preferred Stock [Member]
Convertible preferred stock par value	$ 0.0001	$ 0.0001
Convertible preferred stock shares authorized	714,286	714,286
Convertible preferred stock shares issued	0	0
Convertible preferred stock shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 2,944	$ 2,902	$ 10,258	$ 10,330
Cost of revenues	2,113	1,699	6,645	6,433
Gross profit	831	1,203	3,613	3,897
Operating expenses
Research and development	0	26	6	121
Selling, general and administrative	2,665	2,135	7,030	6,603
Total operating expenses	2,665	2,161	7,036	6,724
Loss from operations	(1,834)	(958)	(3,423)	(2,827)
Interest income (expense), net	1	3	4	(1)
Other income (expense), net	(73)	11	(327)	542
Gain on sale of assets	1	0	1	150
Loss before income taxes	(1,905)	(944)	(3,745)	(2,136)
Income tax benefit (expense)	(34)	0	(98)	(6)
Net loss	$ (1,939)	$ (944)	$ (3,843)	$ (2,142)
Net loss per share: basic	$ (0.62)	$ (0.31)	$ (1.24)	$ (0.85)
Net loss per share: diluted	$ (0.62)	$ (0.31)	$ (1.24)	$ (0.85)
Weighted-average number of shares: basic	3,107	3,080	3,104	2,507
Weighted-average number of shares: diluted	3,107	3,080	3,104	2,507
Other comprehensive loss
Net loss	$ (1,939)	$ (944)	$ (3,843)	$ (2,142)
Foreign currency translation adjustments	235	(65)	136	8
Comprehensive loss	$ (1,704)	$ (1,009)	$ (3,707)	$ (2,134)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (3,843)	$ (2,142)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	91	137
Forgiveness of PPP loan		(723)
Stock-based compensation	569	170
Gain on sale of assets	(1)	(150)
Changes in operating assets and liabilities:
Accounts receivable	129	(58)
Inventories	(162)	(366)
Deferred consideration	129	(2)
Prepaid expenses and other current assets	572	114
Operating lease right-of-use assets	94	148
Accounts payable	(353)	(189)
Accrued expenses and other current liabilities	346	137
Deferred tax asset	(243)	0
Withholding tax payable	259	273
Operating lease liabilities	(94)	(145)
Deferred revenue	(1,204)	(57)
Net cash used in operating activities	(3,711)	(2,853)
Cash flows from investing activities:
Purchases of property and equipment	(79)	(75)
Deposits	(97)	37
Net cash used in investing activities	(176)	(38)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	0	7,554
Proceeds from exercise of common stock options and purchase warrants	0	216
Payments on PPP Loan	(120)	0
Payments on offering costs	(89)	0
Principal payments on long-term debt	(674)	(596)
Net cash provided by (used in) financing activities	(883)	7,174
Effect of exchange rate on cash and cash equivalents	8	26
Net (decrease) increase in cash and cash equivalents	(4,762)	4,309
Cash and cash equivalents, beginning of period	7,396	4,220
Cash and cash equivalents, end of period	2,634	8,529
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 12	$ 12

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Mar. 31, 2021	$ 2	$ 189,217	$ (179,277)	$ (4,579)	$ 5,363
Beginning balance, shares at Mar. 31, 2021	2,092,909
Transaction costs related to ATM agreement offering		(10)			(10)
Employee stock-based compensation expense		56			56
Stock based compensation related to issuance of restricted common stock		3			3
Foreign currency translation adjustment				307	307
Net loss			(1,098)		(1,098)
Ending balance, value at Jun. 30, 2021	$ 2	189,266	(180,375)	(4,272)	4,621
Ending balance, shares at Jun. 30, 2021	2,092,909
Issuance of common stock in connection with ATM, net of transaction costs	$ 1	6,901			6,902
Issuance of common stock in connection with ATM, net of transaction costs, shares	855,500
Issuance of common stock due to options exercises		193			193
Issuance of common stock due to options exercises, shares	44,042
Issuance of common stock due to warrants exercises		23			23
Issuance of common stock due to warrants exercises, shares	12,290
Employee stock-based compensation expense		52			52
Stock based compensation related to issuance of restricted common stock		3			3
Foreign currency translation adjustment				(234)	(234)
Net loss			(100)		(100)
Ending balance, value at Sep. 30, 2021	$ 3	196,438	(180,475)	(4,506)	11,460
Ending balance, shares at Sep. 30, 2021	3,004,741
Shares issued in connection with ATM, net of transaction costs		662			662
Shares issued in connection with ATM, net of transaction costs , shares	94,600
Employee stock-based compensation expense		56			56
Foreign currency translation adjustment				(65)	(65)
Net loss			(944)		(944)
Ending balance, value at Dec. 31, 2021	$ 3	197,156	(181,419)	(4,571)	11,169
Ending balance, shares at Dec. 31, 2021	3,099,341
Beginning balance, value at Mar. 31, 2022	$ 2	197,370	(184,363)	(4,312)	8,697
Beginning balance, shares at Mar. 31, 2022	3,100,937
Employee stock-based compensation expense		214			214
Foreign currency translation adjustment				(65)	(65)
Net loss			(887)		(887)
Ending balance, value at Jun. 30, 2022	$ 2	197,584	(185,250)	(4,377)	7,959
Ending balance, shares at Jun. 30, 2022	3,100,937
Beginning balance, value at Mar. 31, 2022	$ 2	197,370	(184,363)	(4,312)	8,697
Beginning balance, shares at Mar. 31, 2022	3,100,937
Ending balance, value at Dec. 31, 2022	$ 2	197,939	(188,206)	(4,176)	5,559
Ending balance, shares at Dec. 31, 2022	3,109,652
Beginning balance, value at Jun. 30, 2022	$ 2	197,584	(185,250)	(4,377)	7,959
Beginning balance, shares at Jun. 30, 2022	3,100,937
Employee stock-based compensation expense		108			108
Stock based compensation related to issuance of restricted common stock		5			5
Stock based compensation related to issuance of restricted common stock, shares	2,035
Foreign currency translation adjustment				(34)	(34)
Net loss			(1,017)		(1,017)
Ending balance, value at Sep. 30, 2022	$ 2	197,697	(186,267)	(4,411)	7,021
Ending balance, shares at Sep. 30, 2022	3,102,972
Employee stock-based compensation expense		233			233
Stock based compensation related to issuance of restricted common stock		9			9
Stock based compensation related to issuance of restricted common stock, shares	6,680
Foreign currency translation adjustment				235	235
Net loss			(1,939)		(1,939)
Ending balance, value at Dec. 31, 2022	$ 2	$ 197,939	$ (188,206)	$ (4,176)	$ 5,559
Ending balance, shares at Dec. 31, 2022	3,109,652

Organization and Recent Develop

Organization and Recent Developments	9 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Recent Developments	Note 1. Organization and Recent Developments Organization Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company’s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020, and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners in 55 countries worldwide. Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of December 31, 2022 and for the nine months then ended have been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of December 31, 2022, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended December 31, 2022 and 2021, the cash flows for the nine months ended December 31, 2022 and 2021 and the condensed consolidated statement of stockholders’ equity for the three and nine months ended December 31, 2022 and 2021 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the consolidated financial position, operating results and cash flows for the periods presented. The results for the nine months ended December 31, 2022 are not necessarily indicative of results to be expected for the year ending March 31, 2023 or for any future interim period. The condensed consolidated balance sheet at March 31, 2022 has been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2022, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on July 13, 2022.

Liquidity and Financial Conditi

Liquidity and Financial Condition	9 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Financial Condition	Note 2. Liquidity and Financial Condition The Company reported a net loss of $ 1,939,000 3,843,000 188,206,000 184,363,000 7,298,000 10,611,000 2,634,000 7,396,000 3,711,000 Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. Net Loss per Share The following table provides the net loss for each period along with the computation of basic and diluted net loss per share: Computation of earnings per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Denominator: Weighted-average number of common shares outstanding: basic 3,107 3,080 3,104 2,507 Weighted-average number of common shares outstanding: diluted 3,107 3,080 3,104 2,507 Net loss per share: basic $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) Net loss per share: diluted $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) The computation of basic loss per share for the three and nine months ended December 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive. Schedule of antidilutive shares Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Stock options 576 206 576 206 Warrants 108 106 108 106 Common stock units (1) 46 46 46 46 730 358 730 358 ____________ (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license its technology and products. The Company also provides regulatory compliance testing and quality assurance services to medical device and pharmaceutical companies. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned. Sales incentives and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances using the expected value method. The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company assessed the promised goods and services in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation. Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents probable credit losses of $ 0 33,000 81,000 Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision to reduce the carrying amounts of inventories to their net realizable value in the amount of $ 224,000 218,000 Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

Condensed Consolidated Balanc_3

Condensed Consolidated Balance Sheet	9 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Condensed Consolidated Balance Sheet	Note 4. Condensed Consolidated Balance Sheet Inventories, net Inventories, net consist of the following: Schedule of inventories December 31, March 31, 2022 2022 Raw materials $ 1,611,000 $ 1,626,000 Finished goods 1,238,000 1,037,000 Inventories, net $ 2,849,000 $ 2,663,000 Leases The Company's operating leases are comprised primarily of facility leases. The Company did not have any finance leases as of December 31, 2022 and March 31, 2022. Balance sheet information related to our leases is presented below: Lease information December 31, March 31, 2022 2022 Operating leases: Operating lease right-of-use assets $ 471,000 $ 559,000 Operating lease liabilities – current 276,000 250,000 Operating lease liabilities – non-current 195,000 309,000 Other information related to leases is presented below: Nine Months Ended December 31, 2022 Operating lease cost 279,000 Other information: Operating cash flows from operating leases 94,000 Weighted-average remaining lease term – operating leases (in months) 21.5 Weighted-average discount rate – operating leases 6.00 As of December 31, 2022, the annual minimum lease payments of our operating lease liabilities were as follows: Schedule of minimum operating lease liabilities For Years Ending March 31, 2023 (excluding the nine months ended December 31, 2022) $ 82,000 2024 294,000 2025 143,000 2026 15,000 Total future minimum lease payments, undiscounted 534,000 Less: imputed interest (63,000 ) Present value of future minimum lease payments $ 471,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies Legal Matters The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss. Employment Agreements As of December 31, 2022, the Company had employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these agreements, at December 31, 2022, aggregated annual salaries would be $ 575,000 575,000 Related Party Transactions Ms. Trombly was appointed the Chief Executive Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC, which has been retained by the Company to advise on certain corporate and securities law matters. During the year ended March 31, 2022, the Company incurred $ 170,000 27,000

Debt

Debt	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 6. Debt Financing of Insurance Premiums On February 1, 2022, the Company entered into a note agreement for $ 748,000 4.68 76,000 Paycheck Protection Program Loan On May 1, 2020, the Company received loan proceeds in the amount of $ 1,310,000 The unsecured loan, which was in the form of a note dated April 29, 2020, matured on April 29, 2022 1 723,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 7. Stockholders’ Equity Authorized Capital The Company is authorized to issue up to 24,000,000 0.0001 714,286 0.0001

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8. Stock-Based Compensation Stock-based compensation expense is as follows: Employee stock-based compensation expense Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Cost of revenues $ – $ – $ – $ – Research and development – – – – Selling, general and administrative 242 56 569 170 Total stock-based compensation $ 242 $ 56 $ 569 $ 170 At December 31, 2022, there were unrecognized compensation costs of $ 686,000 2.00 Stock options award activity is as follows: Schedule of option activity Number of Weighted- Outstanding at April 1, 2022 466,234 $ 12.09 Options granted 191,082 1.11 Options exercised – – Options forfeited (58,165 ) 5.67 Options expired (23,605 ) 19.24 Outstanding at December 31, 2022 575,546 $ 8.80 Exercisable at December 31, 2022 214,626 $ 18.28 The aggregate intrinsic value of stock options of zero is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $ 1.12 The Company did not capitalize any cost associated with stock-based compensation. The Company issues new shares of common stock upon exercise of stock-based awards.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter. Our effective tax rate for the nine months and three months ended December 31, 2022 was - 2.69 1.68 21 Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of December 31, 2022, the Company continues to maintain a valuation allowance in U.S.

Revenue Disaggregation

Revenue Disaggregation	9 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Disaggregation	Note 10. Revenue Disaggregation The Company generates revenues from products which are sold into the human and animal healthcare markets and to multiple geographic regions. The following table presents the Company’s disaggregated revenues by revenue source: Disaggregated Revenue by Source Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Human Care $ 2,435 $ 2,015 $ 7,050 $ 7,201 Animal Care 434 818 1,957 2,755 Service and Royalty 75 69 1,251 374 $ 2,944 $ 2,902 $ 10,258 $ 10,330 The following table shows the Company’s revenues by geographic region: Schedule of geographic sales Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 United States $ 761 $ 933 $ 2,603 $ 3,872 Europe 1,104 731 3,117 2,419 Asia 514 664 1,952 1,810 Latin America 384 273 1,827 1,356 Rest of the World 181 301 759 873 Total $ 2,944 $ 2,902 $ 10,258 $ 10,330

Significant Customer Concentrat

Significant Customer Concentrations	9 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Significant Customer Concentrations	Note 11. Significant Customer Concentrations For the three months ended December 31, 2022, customer A represented 13 11 11 22 18 16 10 23 13 At December 31, 2022, customer D represented 18 12 10 20 15 14

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events At-The-Market Offering Agreement On December 23, 2022, the Company entered into an At-The-Market Offering Agreement, or ATM Agreement, with Ladenburg Thalmann & Co. Inc., as sales agent, pursuant to which the Company may offer and sell, from time to time, through Ladenburg, shares of its common stock, $0.0001 par value per share. The Company agreed to pay Ladenburg a commission of 3% of the aggregate gross proceeds from each sale of shares. From January 4, 2023 through February 2, 2023, the Company sold an aggregate of 1,535,718 shares of common stock for gross proceeds of $2,699,906 and net proceeds of $2,533,438 after deducting commissions and other offering expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and derivative instruments, and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.
Net Loss per Share	Net Loss per Share The following table provides the net loss for each period along with the computation of basic and diluted net loss per share: Computation of earnings per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Denominator: Weighted-average number of common shares outstanding: basic 3,107 3,080 3,104 2,507 Weighted-average number of common shares outstanding: diluted 3,107 3,080 3,104 2,507 Net loss per share: basic $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) Net loss per share: diluted $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) The computation of basic loss per share for the three and nine months ended December 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive. Schedule of antidilutive shares Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Stock options 576 206 576 206 Warrants 108 106 108 106 Common stock units (1) 46 46 46 46 730 358 730 358 ____________ (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license its technology and products. The Company also provides regulatory compliance testing and quality assurance services to medical device and pharmaceutical companies. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled. For all of its sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned. Sales incentives and other programs that the Company may make available to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances using the expected value method. The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program. Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor. The Company assessed the promised goods and services in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends. The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents probable credit losses of $ 0 33,000 81,000
Inventories	Inventories Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value. Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision to reduce the carrying amounts of inventories to their net realizable value in the amount of $ 224,000 218,000
Recent Accounting Standards	Recent Accounting Standards Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Computation of earnings per share	Computation of earnings per share Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Denominator: Weighted-average number of common shares outstanding: basic 3,107 3,080 3,104 2,507 Weighted-average number of common shares outstanding: diluted 3,107 3,080 3,104 2,507 Net loss per share: basic $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) Net loss per share: diluted $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 )
Schedule of antidilutive shares	Schedule of antidilutive shares Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Stock options 576 206 576 206 Warrants 108 106 108 106 Common stock units (1) 46 46 46 46 730 358 730 358 ____________ (1) Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock

Condensed Consolidated Balanc_4

Condensed Consolidated Balance Sheet (Tables)	9 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of inventories	Schedule of inventories December 31, March 31, 2022 2022 Raw materials $ 1,611,000 $ 1,626,000 Finished goods 1,238,000 1,037,000 Inventories, net $ 2,849,000 $ 2,663,000
Lease information	Lease information December 31, March 31, 2022 2022 Operating leases: Operating lease right-of-use assets $ 471,000 $ 559,000 Operating lease liabilities – current 276,000 250,000 Operating lease liabilities – non-current 195,000 309,000 Other information related to leases is presented below: Nine Months Ended December 31, 2022 Operating lease cost 279,000 Other information: Operating cash flows from operating leases 94,000 Weighted-average remaining lease term – operating leases (in months) 21.5 Weighted-average discount rate – operating leases 6.00
Schedule of minimum operating lease liabilities	Schedule of minimum operating lease liabilities For Years Ending March 31, 2023 (excluding the nine months ended December 31, 2022) $ 82,000 2024 294,000 2025 143,000 2026 15,000 Total future minimum lease payments, undiscounted 534,000 Less: imputed interest (63,000 ) Present value of future minimum lease payments $ 471,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Employee stock-based compensation expense	Employee stock-based compensation expense Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Cost of revenues $ – $ – $ – $ – Research and development – – – – Selling, general and administrative 242 56 569 170 Total stock-based compensation $ 242 $ 56 $ 569 $ 170
Schedule of option activity	Schedule of option activity Number of Weighted- Outstanding at April 1, 2022 466,234 $ 12.09 Options granted 191,082 1.11 Options exercised – – Options forfeited (58,165 ) 5.67 Options expired (23,605 ) 19.24 Outstanding at December 31, 2022 575,546 $ 8.80 Exercisable at December 31, 2022 214,626 $ 18.28

Revenue Disaggregation (Tables)

Revenue Disaggregation (Tables)	9 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregated Revenue by Source	Disaggregated Revenue by Source Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 Human Care $ 2,435 $ 2,015 $ 7,050 $ 7,201 Animal Care 434 818 1,957 2,755 Service and Royalty 75 69 1,251 374 $ 2,944 $ 2,902 $ 10,258 $ 10,330
Schedule of geographic sales	Schedule of geographic sales Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2022 2021 2022 2021 United States $ 761 $ 933 $ 2,603 $ 3,872 Europe 1,104 731 3,117 2,419 Asia 514 664 1,952 1,810 Latin America 384 273 1,827 1,356 Rest of the World 181 301 759 873 Total $ 2,944 $ 2,902 $ 10,258 $ 10,330

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,939	$ 944	$ 3,843	$ 2,142
Accumulated deficit	188,206		188,206		$ 184,363
Working capital	7,298		7,298		10,611
Cash	$ 2,634		2,634		$ 7,396
Net cash used in operating activities			$ 3,711	$ 2,853

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss	$ (1,939)	$ (944)	$ (3,843)	$ (2,142)
Denominator:
Weighted-average number of common shares outstanding: basic	3,107	3,080	3,104	2,507
Weighted-average number of common shares outstanding: diluted	3,107	3,080	3,104	2,507
Net loss per share: basic	$ (0.62)	$ (0.31)	$ (1.24)	$ (0.85)
Net loss per share: diluted	$ (0.62)	$ (0.31)	$ (1.24)	$ (0.85)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares shares in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		730	358	730	358
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		576	206	576	206
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		108	106	108	106
Common Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	[1]	46	46	46	46
[1]Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 0	$ 0
Allowance for sales discounts, rebates, distributor fees and returns	33,000	81,000
Inventory reserves	$ 224,000	$ 218,000

Condensed Consolidated Balanc_5

Condensed Consolidated Balance Sheets (Details - Inventories) - USD ($) $ in Thousands	Dec. 31, 2022	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Raw materials	$ 1,611	$ 1,626
Finished goods	1,238	1,037
Inventories, net	$ 2,849	$ 2,663

Condensed Consolidated Balanc_6

Condensed Consolidated Balance Sheets (Details - Operating lease information) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Operating lease right-of-use assets	$ 471	$ 559
Operating lease liabilities – current	276	250
Operating lease liabilities – non-current	195	$ 309
Operating lease cost	279
Operating cash flows from operating leases	$ 94
Operating Lease, Weighted Average Remaining Lease Term	21 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent	6%

Condensed Consolidated Balanc_7

Condensed Consolidated Balance Sheets (Details - Minimum Operating lease payments) $ in Thousands	Dec. 31, 2022 USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
2023 (excluding the nine months ended December 31, 2022)	$ 82
2024	294
2025	143
2026	15
Total future minimum lease payments, undiscounted	534
Less: imputed interest	(63)
Present value of future minimum lease payments	$ 471

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Annual salaries	$ 575,000
Potential severance	575,000
Trombly Business Law [Member]
Defined Benefit Plan Disclosure [Line Items]
Legal fees	$ 27,000	$ 170,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)			9 Months Ended	10 Months Ended
	Jan. 31, 2022	May 01, 2020	Dec. 31, 2022	Dec. 31, 2022
Short-Term Debt [Line Items]
Approval for forgiveness			$ 723,000
Paycheck Protection Program [Member] | States Bank In Atlanta [Member]
Short-Term Debt [Line Items]
Debt interest rate			1%
Proceeds from loan		$ 1,310,000
Debt Instrument, Maturity Date			Apr. 29, 2022
Insurance Premiums 2 [Member]
Short-Term Debt [Line Items]
Debt face amount	$ 748,000
Debt interest rate	4.68%
Principal payments made				$ 76,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized	24,000,000	24,000,000
Common stock par value	$ 0.0001	$ 0.0001
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	714,286	714,286
Preferred stock par value	$ 0.0001	$ 0.0001

Stock-Based Compensation (Detai

Stock-Based Compensation (Details-Stock-based compensation) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 242	$ 56	$ 569	$ 170
Cost of Sales [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	0	0	0	0
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	0	0	0	0
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 242	$ 56	$ 569	$ 170

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details-Option activity) - Equity Option [Member]	9 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Outstanding at beginning of period | shares	466,234
Weighted- Average Exercise Price Outstanding at beginning of period | $ / shares	$ 12.09
Number of Shares Options granted | shares	191,082
Weighted- Average Exercise Price Options granted | $ / shares	$ 1.11
Number of Shares Options exercised | shares	0
Weighted- Average Exercise Price Options exercised | $ / shares	$ 0
Number of Shares Options forfeited | shares	(58,165)
Weighted- Average Exercise Price Options forfeited | $ / shares	$ 5.67
Number of Shares Options expired | shares	(23,605)
Weighted- Average Exercise Price Options expired | $ / shares	$ 19.24
Number of Shares Outstanding at end of period | shares	575,546
Weighted- Average Exercise Price Outstanding at end of period | $ / shares	$ 8.80
Number of Shares Exercisable at end of period | shares	214,626
Weighted- Average Exercise Price Exercisable at end of period | $ / shares	$ 18.28

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Narrative) - Equity Option [Member]	9 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs | $	$ 686,000
Weighted average amortization period	2 years
Aggregate intrinsic value per share | $ / shares	$ 1.12

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	1.68%	2.69%
Effective federal statutory tax rate	21%	21%

Revenue Disaggregation (Details

Revenue Disaggregation (Details - Disaggregation of revenue) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 2,944	$ 2,902	$ 10,258	$ 10,330
Product [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,944	2,902	10,258	10,330
Product [Member] | Human Care [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,435	2,015	7,050	7,201
Product [Member] | Animal Care [Member]
Disaggregation of Revenue [Line Items]
Revenues	434	818	1,957	2,755
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 75	$ 69	$ 1,251	$ 374

Revenue Disaggregation (Detai_2

Revenue Disaggregation (Details - Geographic regions) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 2,944	$ 2,902	$ 10,258	$ 10,330
Product [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,944	2,902	10,258	10,330
Product [Member] | Revenue, Segment Benchmark [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	761	933	2,603	3,872
Product [Member] | Revenue, Segment Benchmark [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,104	731	3,117	2,419
Product [Member] | Revenue, Segment Benchmark [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenues	514	664	1,952	1,810
Product [Member] | Revenue, Segment Benchmark [Member] | Latin America [Member]
Disaggregation of Revenue [Line Items]
Revenues	384	273	1,827	1,356
Product [Member] | Revenue, Segment Benchmark [Member] | Rest Of The World [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 181	$ 301	$ 759	$ 873

Significant Customer Concentr_2

Significant Customer Concentrations (Details Narrative) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Revenue Benchmark [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	13%		18%	13%
Revenue Benchmark [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	11%	22%	16%	23%
Revenue Benchmark [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	11%		10%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage					20%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			12%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			18%		15%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			10%
Accounts Receivable [Member] | Customer F [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage					14%